ETP-46464

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

ETP-46464

CAS No. : 1345675-02-6

MCE 国际站：ETP-46464

产品活性：ETP-46464 是一种有效的 mTOR 和 ATR 抑制剂，IC₅₀ 分别为 0.6 和 14 nM。

研究领域：PI3K/Akt/mTOR  |  Cell Cycle/DNA Damage

作用靶点：mTOR  |  ATM/ATR

In Vitro: ETP-46464 (ATRi) also inhibits DNA-PK, PI3Kα and ATM with IC₅₀s of 36 nM, 170 nM and 545 nM, respectively. Platinum-sensitive and -resistant ovarian, endometrial and cervical cancer cell lines are treated with varying levels of Cisplatin (0-50 µM) with or without the ETP-46464 (5.0 µM) and/or the KU55933 (10.0 µM) for 72 h. Single-agent dose response analyses of ETP-46464 and KU55933 in a subset of cell lines reveal a wide LD₅₀ range of 10.0±8.7 and 38.3±7.6 µM respectively. Co-treatment doses are chosen based on these studies and previously published evidence of phospho-Chk1 (Ser345) and phospho-ATM (Ser1981) inhibition following ionizing radiation exposure and dose response treatments with ETP-46464 and KU55933. Treatment with ETP-46464 significantly increases the response of Cisplatin in all cell lines tested, resulting in 52-89% enhancement in activity and are synergistic. The combined inhibition of ATR and ATM enhances the response of Cisplatin to a level equivalent to that observed using ETP-46464 alone. These effects are independent of p53 status, and are observed in all gynecologic (GYN) cancer cells tested. Treatment with ETP-46464, but not KU55933, not only sensitizes these GYN cancer cell lines to Cisplatin, but also enhances the response of Carboplatin.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Antioxidant Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Mitochondrial Protection Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  Rapamycin  |  Everolimus  |  MHY1485  |  Torin 1  |  Ceralasertib  |  AZD-7648  |  AZD-8055  |  KU-55933  |  Sapanisertib  |  Dactolisib  |  Salidroside  |  AZD1390  |  Torin 2  |  Temsirolimus  |  KU-60019  |  AZD0156  |  L-Leucine  |  Elimusertib  |  3BDO  |  JR-AB2-011  |  VE-821  |  Omipalisib  |  PI-103  |  Torkinib  |  Camonsertib  |  Dihydromyricetin  |  NV-5138  |  RMC-5552  |  Mirin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds